替莫唑胺对1p/19q共缺失低级别胶质瘤生长动力学的长期影响
该回顾性研究基于系列磁共振图像评估了36例接受一线替莫唑胺治疗的进展性1p/19q共缺失低级别胶质瘤患者的平均肿瘤直径演变。替莫唑胺开始后94.4%患者平均肿瘤直径持续下降,中位持续23个月;3年和5年再生长率分别为77%和94%。基于体积分析的无进展生存期短于RANO双径标准(23 vs 35个月,p=0.05)及至下次肿瘤治疗时间(23 vs 46个月,p=0.001)。
要点
- 替莫唑胺开始后94.4%的1p/19q共缺失低级别胶质瘤患者平均肿瘤直径持续下降,中位持续23个月。
- 替莫唑胺开始后3年和5年平均肿瘤直径再生长率分别为77%和94%。
- 基于体积分析的肿瘤进展时间短于RANO双径标准(23 vs 35个月,p=0.05)。
核心结论
- 体积分析对精确评估1p/19q共缺失低级别胶质瘤化疗疗效、识别早期肿瘤进展和避免无效化疗继续很重要。
- 本系列中虽观察到部分持久体积缓解,但大多数肿瘤在替莫唑胺开始后3年内恢复生长。
研究设计与样本
- 基于系列磁共振图像的回顾性评估,纳入36例接受一线替莫唑胺治疗的进展性1p/19q共缺失低级别胶质瘤患者,评估平均肿瘤直径演变。
主要发现
- 替莫唑胺开始后,除2例(94.4%)外所有患者平均肿瘤直径进行性下降,中位持续23个月(范围3-114)。
- 10例(27%)在替莫唑胺治疗期间出现平均肿瘤直径再生长,22例(66%)在替莫唑胺停药后出现再生长。
- 这些患者中,替莫唑胺停药后至平均肿瘤直径再生长中位时间为12个月(范围1-88)。
- 替莫唑胺开始后3年和5年平均肿瘤直径再生长率分别为77%和94%。
- 基于体积分析的肿瘤进展时间短于基于RANO双径标准的肿瘤进展时间(23 vs 35个月,p=0.05),也短于至下次肿瘤治疗时间(23 vs 46个月,p=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined. Based on serial magnetic resonance images we retrospectively evaluated the evolution of the mean tumor diameter (MTD) in 36 progressive 1p/19q-codeleted LGG treated with upfront TMZ. After TMZ onset, all but two patients (94.4%) presented a progressive MTD decrease that lasted for a median duration of 23 months (range 3-114). In 10 patients (27%) MTD regrowth occurred during TMZ treatment and in 22 patients (66%) after TMZ discontinuation. In these patients, median time to MTD regrowth after TMZ discontinuation was 12 months (range 1-88). The rate of MTD regrowth at 3 and 5 years after TMZ onset was 77 and 94%, respectively. Time to tumor progression (TTP) based on volumetric analysis was shorter than TTP based on Response Assessment in Neuro-Oncology (RANO) bidimensional criteria (23 vs. 35 months, p = 0.05) and shorter than time to next oncological treatment (23 vs. 46 months, p = 0.001). In 10 patients (27%), absence of volumetric analysis led to continue TMZ for a median of 10 cycles after MTD had started to regrow. Volumetric analysis is important to precisely assess chemotherapy efficacy in 1p/19q-codeleted LGG, identify early tumor progression and avoid futile chemotherapy continuation. In the present series, although some long-lasting volumetric responses were observed, most tumors resumed their growth within 3 years after TMZ onset.
引用
- Izquierdo C, Alentorn A, Idbaih A, et al. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. J Neurooncol. 2017. PMID: 29143276. doi:10.1007/s11060-017-2677-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。